Aeolus Pharmaceuticals Corporation (formerly Incara Pharmaceuticals Corporation) is developing a new class of small molecule catalytic antioxidants that destroy oxygen-derived free radicals, believed to be important contributors to the pathogenesis of many diseases. In addition to ALS (Lou Gehrigs disease), Incaras catalytic antioxidants have been shown to reduce damage to tissue in animal studies of neurological disorders such as stroke, and in other non-neurological indications such as cancer radiation therapy, chronic bronchitis and asthma
